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Abstract
ANK3 encodes multiple isoforms of ankyrin-G, resulting in variegated tissue expression and function, especially regarding 
its role in neuronal development. Based on the zygosity, location, and type, ANK3 variants result in different neurodevelop-
mental phenotypes. Autism spectrum disorder has been associated with heterozygous missense variants in ANK3, whereas 
a more severe neurodevelopmental phenotype is caused by isoform-dependent, autosomal-dominant, or autosomal-recessive 
loss-of-function variants. Here, we present four individuals affected by a variable neurodevelopmental phenotype harbor-
ing a heterozygous frameshift or nonsense variant affecting all ANK3 transcripts. Thus, we provide further evidence of an 
isoform-based phenotypic continuum underlying ANK3-associated pathologies and expand its phenotypic spectrum.
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Introduction
ANK3 codes for a large ankyrin, ankyrin-G, which is inte-
gral for spectrin-actin cytoskeleton membrane stability and 
scaffolding [1, 2]. It plays an important role in neuronal 
development, cell motility, proliferation, and signaling as 
well as the maintenance of specialized membrane domains 
and the targeting of ion channels and cell adhesion mol-
ecules [3–6]. It was initially identified in neurons in the 
central and peripheral nervous system, namely the nodes of 
Ranvier and the axon initial segment (AIS) [5, 7]. Like other 
members of the ankyrin family, ankyrin-G consists of four 
functional domains: an amino-terminal domain containing 
multiple ankyrin-repeats, a central spectrin-binding domain, 
a serine-threonine-rich neurospecific domain, and a carboxy-
terminal regulatory death [8, 9].
There are multiple isoforms of ANK3 which are develop-
mentally regulated and differentially expressed due to tissue-
specific splicing [10, 11]. Notably, three major brain-specific 
isoforms of 190 kDa, 270 kDa, and 480 kDa (giant AnkG) 
have been identified, each having a unique neuronal circuit 
function and distribution pattern [5, 12–15]. The 190-kDA 
ANK3 isoform regulates dendritic spine morphology and 
N-methyl-D-aspartate (NMDA) receptor trafficking and is 
expressed almost ubiquitously in the brain [15]. The two big-
ger brain-specific isoforms sustain the myelin sheaths and play 
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an important part in the formation of the nodes of Ranvier as 
well as the regulation of somatodendritic GABAergic synapses 
[12–14].
In line with its predominant neurological functions, 
pathogenic variants in ANK3 have been linked to a broad 
range of neurological diseases, such as autism spectrum 
disorder (ASD), schizophrenia, bipolar disorder, and, more 
recently, intellectual disability (ID), epileptic encephalop-
athy, and behavioral abnormalities including a sleep and/
or attention-deficit hyperactivity disorder (ADHD) [1, 9, 
16–21]. In 2017, we reported the first individual harboring 
a heterozygous de novo nonsense variant which affected all 
three ANK3 isoforms who presented with mild intellectual 
disability, autistic, and behavioral abnormalities [21]. We 
and others [22] postulated an isoform-specific phenotypic 
continuum for missense and truncating variants affecting 
different brain-specific isoforms of ANK3, resulting in an 
array of neurological features depending on the zygosity, 
location and type of variant, and the isoform affected [21].
Here, we present four novel heterozygous loss-of-function 
(LOF) variants affecting all isoforms of ANK3. The highly 
variable severity of cognitive impairment and other symp-
toms in these patients further backs the claim of an isoform-




All biological samples were obtained following written 
informed consent from studied individuals or their legal rep-
resentatives. The study was performed in accordance with 
protocols approved by the Ethics Committee of the Hamburg 
Chamber of Physicians (PV 3802). The study was performed 
in accordance with the Declaration of Helsinki protocols.
Genetic analyses
Genomic DNA was isolated from whole blood samples 
using standard procedures. Whole-exome sequencing (WES) 
in individuals 1 and 3, and trio whole-exome sequencing 
(trio-WES) in individuals 2 and 4, data annotation, and inter-




Proband 1 is the first child of non-related, healthy Caucasian 
parents. He was born at term after an uneventful pregnancy 
with a slightly reduced birth weight 2790 g (3rd percen-
tile, − 1.89z), length 50 cm (− 1.09z), and occipitofrontal 
head circumference (OFC) 34 cm (− 1.23z), APGAR 10/10. 
At 2 years, speech delay was diagnosed. Motor develop-
ment and brain MRI were unremarkable. At 5 years, the last 
clinical examination revealed intellectual disability (SON-IQ 
55), speech delay (level of speech at 4.2 years at least 2 years 
delayed), and suspicion of ASD (not formally tested). His 
last body measurements were within the normal range; he 
showed no signs of seizures, muscular hypotonia, or spastic-
ity. Facial dysmorphism was not reported.
Proband 2 is the first and only child of non-related, 
healthy Caucasian parents. He was born after an uneventful 
pregnancy at 39 weeks of gestation with unremarkable birth 
weight 3290 g (− 0.45z), length 50 cm (− 0.83z), and OFC 
34 cm (− 1z), APGAR 10/10. Developmental delay became 
evident at 6 months. Seizures initially presented as infantile 
spasms, with a diagnosis of West syndrome subsequently 
made due hypsarrhythmia in interictal EEG. Brain MRI 
revealed anomalies consistent with a type 1 lissencephaly. 
Swallowing and breathing difficulties were accompanied by 
recurrent pneumonia, and he required a percutaneous endo-
scopic gastrostomy (PEG). At 7 years (Fig. 1a), the most 
recent clinical examination revealed severe global develop-
mental delay, lack of gross, and fine motor development with 
involuntary repetitive stereotype movements (rotation of 
the whole body; flexion–extension movement of the limbs), 
severe axial hypotonia (no head control, nor sitting or any 
controlled movement), cognitive impairment, absent social 
eye contact, divergent strabismus, and absent speech. Sei-
zures were recurring and EEG remained abnormal. His latest 
measurements showed progressive, secondary microcephaly, 
and mild dystrophy (head circumference 47.5 cm (− 3.88z), 
weight 18 kg (− 2.27z), height 117 cm (− 1.38z)). Facial 
dysmorphism was not reported. Fragile X and array-CGH 
analyses yielded normal results.
Proband 3 is the first child of non-related, healthy Cau-
casian parents. Her father passed away in an accident. She 
has a full sibling and two maternal half siblings who have 
no learning difficulties. She was born after an uneventful 
pregnancy at 38 weeks gestation with normal measure-
ments. Meconium was present at delivery, APGAR 6/7. 
She required a 3-day NICU admission, treated for presumed 
infection due to apneas, poor feeding, and unstable tempera-
ture. She presented with mildly delayed motor development 
(unaided walking at 18 months). Although first words report-
edly occurred around the first year, due to significant speech 
delay she received speech therapy in preschool. In kindergar-
ten she struggled with completing tasks and understanding 
concepts and was subsequently home-schooled. At 13 years 
psychoeducational testing showed a FSIQ of 68. Autistic 
features were not noted but she is shy and quiet. At 14 years, 
she was operating at a grade 2–3 level. She had a compound 
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melanocytic nevus removed at age 11 years. There were no 
vision or hearing concerns, no history of seizures nor gait 
abnormality or stereotypic movements. Puberty was normal 
with menses starting at 12 years. Her latest clinical exami-
nation at 14 years showed an increased head circumference 
at 58 cm (+ 2.6z) and normal weight 66.15 kg (+ 1.1z) and 
height 169.3 cm (+ 1z). A mildly triangular face, small 
chin and prominent lower lip vermilion were noted (see 
Fig. 1a). Chromosomal microarray and fragile X testing 
were unremarkable.
Proband 4 is the second child of non-related, healthy Cau-
casian parents. His elder brother had mild speech difficulties 
and behavioral problems; genetic testing for the familial ANK3 
variant was unremarkable (additional patient characteristics 
are given in Online Resource 1). Two paternal cousins were 
thought to have developmental delay, however, contact was 
limited and no further information could be obtained. Proband 
4 was born after an uneventful pregnancy at 35 weeks of gesta-
tion. Birth measurements were unremarkable; APGAR 8/9. He 
initially required a feeding tube; cerebral ultrasound indicated a 
low-grade intracerebral hemorrhage which was not detectable 
in later examinations. Delayed motor development was noted 
at 4 months, and motor milestones continued to be delayed 
throughout childhood (e.g. supported sitting with 12 months, 
unassisted walking with 3 years). At 11 years he could run 
and use a tricycle (no swimming, no bicycle). Expressive and 
receptive language skills were profoundly impaired (active lan-
guage of ~ 10 words) and he communicated using a language 
computer. Slow but continuous progress regarding verbal and 
motor development without signs of regression was reported. 
He attended special school, as writing and reading skills had 
not been achieved. Social interaction, sleeping and eating 
behavior were unremarkable. However, he displayed repetitive 
stereotypic movements. At the latest examination his weight 
was 36.6 kg (+ 0.1z), body length was 131 cm (− 1.9z) and 
OFC was 52 cm (− 1.4z). Hearing and ophthalmologic exami-
nation, extensive laboratory work-up (including endocrine and 
metabolic analyses) gave normal results. His EEGs showed 
markers for an increased susceptibility to seizures. Brain MRI 
detected multiple flair hyperintensities of the white matter 
periventricular and hypoplastic corpus callosum. Facially, a 
short philtrum and thin upper lip vermillion were noted (see 
Fig. 1b).
WES analyses
Duo-WES with samples of the proband 1 and his mother 
revealed a heterozygous 1 bp-deletion in ANK3, c.2050delG, 
p.(Leu684Serfs*7) that was absent in the mother. Trio-WES 
analysis in probands 2 and 4 revealed in each a novel de 
novo heterozygous 1 bp-deletion in ANK3, c.127delG and 
c.3303delC, p.(Ala43Glnfs*4) and p.(Glu1102Serfs*16), 
respectively. Duo-WES in proband 3 and her mother revealed 
a heterozygous single-nucleotide variant in ANK3, c.769C > T, 
p.(Arg257*), which was not maternally inherited. Paternal DNA 
samples of probands 1 and 3 were unavailable for testing. None 
of these variants were present in the gnomAD dataset v2.1.1. All 
four variants affected all three ANK3 isoforms (Fig. 2) and likely 
activate nonsense-mediated mRNA decay (NMD).
Discussion
Different types of variants affecting in part different iso-
forms of the ANK3 gene have been associated with a wide 
array of neurological pathologies [1, 9, 17, 18, 20–22]. A 
Fig. 1  Photographs of the 
probands 3 and 4. a Frontal 
photographs of proband 3: 
mildly triangular face, small 
chin, and prominent lower lip 
vermilion; b frontal photo-
graphs of proband 4: short 




genotypic-phenotypic continuum for missense and non-
sense mutations in ANK3 has been proposed and poten-
tially offers an explanation for the highly variable sever-
ity of the neurological and neurodevelopmental symptoms 
[22]. Autosomal recessive missense variants that disturb 
the transition of giant AnkG from a closed to an open con-
formation have been identified in two individuals affected 
by a varied spectrum of neurodevelopmental clinical signs 
and symptoms [9]. Similar clinical outcome was observed 
in cases harboring homozygous frameshift variants that 
also affect only the largest 480-kDa isoform [22]. Moreo-
ver, heterozygous missense variants have been associated 
with a milder clinical spectrum ranging from ASD to neu-
ropsychiatric disorders like schizophrenia and bipolar dis-
order [1, 16–18]. In addition, heterozygous loss-of-func-
tion (LOF) variants affecting all brain-specific isoforms 
of ANK3 have been identified in individuals affected by 
a neurodevelopmental disorder [21, 22]. Here we report 
four additional unrelated individuals harboring heterozy-
gous LOF variants affecting all three major brain ANK3 
isoforms. Interestingly, they display a varied spectrum of 
neurodevelopmental phenotypes (see Table 1).
All four presented with intellectual disability and 
speech delay, similar to two previously reported cases 
bearing similar ANK3 loss-of-function variants [21, 22]. 
Autistic features and delay in motor development, at least 
mild, were observed in three individuals. Muscular hypo-
tonia was present in two individuals, in one of them severe. 
Brain MRI was conducted in two individuals: it showed 
type 1 lissencephaly in the most severely affected proband 
2, whereas proband 4 presented with multiple white 
matter hyperintensities and hypoplastic corpus callosum. 
Epilepsy was diagnosed in proband 2 (West syndrome), 
whereas proband 4 showed markers for a susceptibility to 
seizures on EEG without clinical seizures. Macrocephaly 
that we previously reported [21] was described only in 
proband 3, while the lissencephalic patient developed sec-
ondary microcephaly; the two other probands presented 
with unremarkable OFCs.
Noteworthy, proband 2 presented with the most severe 
clinical course of all so far known individuals harboring a 
LOF variant. Interestingly, p.(Ala43Glnfs*4) is the most 
N-terminally located LOF variant that has been identi-
fied so far, and performed trio-WES analysis detected no 
other likely pathogenic variants. This variant will most 
likely lead to haploinsufficiency, representing a fully non-
functional protein or null-allele. One possibility for the 
more severe clinical course of this individual as compared 
to the other ones presented here or previously [21, 22], 
could be that the more C-terminal nonsense and frameshift 
variants still result in a stable but truncated protein which 
does retain some of the ANK3 function. Clearly, western 
blot analyses utilizing proband-derived primary material, 
which was unfortunately not available here, are needed to 
clarify this. It is also worth noting that we cannot com-
pletely exclude the possibility that proband 2 harbors a 
further distinct genetic factor that has not been covered 
by WES.
However, as brain anomalies were detected in proband 
4 and proband 3 had low IQ and macrocephaly, sug-
gesting brain anomalies although brain imaging was not 
conducted, structural brain anomalies may represent an 
Fig. 2  Protein structure of the three ANK3 isoforms with indi-
cated positions of identified loss-of-function variants (as previously 
described by Kloth et al., 2017). Red arrows indicate position of the 
here identified heterozygous variants; black arrows indicate position 
of the previously reported variants affecting all three ANK3 isoforms 
and gray arrows indicate previously reported homozygous variants 
affecting only a single ANK3 isoform
266 neurogenetics (2021) 22:263–269
1 3












Sex Male Male Female Male Male Male
Genotype Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous
Not present in the 
mother, father n/a
De novo Not present in 
the mother, 
father n/a
De novo De novo n/a
1 bp deletion 1 bp deletion Nonsense 1 bp deletion Nonsense Translocation
Age at last 
examination




IQ at the age of 4.5 
y: SON-IQ 55
 +  + 
IQ at age 13 y: 
FSIQ 68















-  + 
(severe, no head 
control)
-  +  +  + 
Spasticity -  + - - - -
Stereotypic limb 
movements
-  + -  + - -
(repetitive behav-
ior)
Hyperactivity - - - -  +  + 




(described as shy 
and quiet)
-  +  + 






Aggressiveness - - - -  +  + 
Sleeping dis-
order
- - - -  +  + 
Chronic hunger - - -
Poor feeding in 
infancy
-  + n/a
Dysmorphic 
features























(feeding difficulties in 
infancy)
 + n/a
cCT/brain MRI Not done Type 1 lissen-
cephaly
Not done Multiple flair hyper-
intensities within 
the white matter, 
periventricular, pari-






expansion of the clinical spectrum of ANK3‐related disor-
ders. Thus, it might be warranted to perform singular brain 
scan in every individual harboring a likely pathogenic 
ANK3 variant and to consider ANK3 analysis in undiag-
nosed cases with structural brain anomalies. Additionally, 
two of the four probands presented with repetitive stereo-
typic movements. Since a stereotypic movement disorder 
(SMD) was not formally diagnosed, it remains difficult to 
differentiate between SMD and stereotypic autistic behav-
ior—but stereotypic limb movements might represent a 
novel ANK3-related symptom. Notably, aggressiveness, 
hyperactivity, signs of a sleeping disorder, or chronic hun-
ger remain unique to the individual we reported previ-
ously [21]. In line with our previous report, there were no 
recognizable dysmorphic features in this cohort; although 
mild variations of the lips, philtrum and/or chin area were 
described in two individuals (see Fig. 1a + b). Thus, as 
of now, we would not reliably consider these features 
part ANK3-associated phenotype. Further clinical reports 
beyond the probands identified in this study are needed to 
elucidate the full phenotypic spectrum and broaden geno-
type–phenotype correlations. The latter especially holds 
true for the occurrence and degree of speech delay, intel-
lectual disability, neuromuscular involvement, structural 
brain anomalies, epilepsy, and behavioral abnormalities.
Taken together, this cohort allows an expansion of the 
ANK3-mediated clinical spectrum and adds further evi-
dence to the existence of an autosomal dominant ANK3-
related neurodevelopmental disorder as well as an iso-
form-based, phenotypic continuum between dominant and 
recessive ANK3-associated pathologies.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s10048- 021- 00655-4.
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